Stock of the Day

March 24, 2020

NeoGenomics (NEO)

$16.65
-$0.60 (-3.5%)
Market Cap: $2.22B

About NeoGenomics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Trend

NeoGenomics, Inc. (NASDAQ: NEO) shares have decreased as investors weigh a leadership transition against better-than-expected operating guidance and continued analyst support. The immediate pressure appears tied to uncertainty surrounding the company’s CEO succession plan.

  • BTIG upgraded NeoGenomics to Buy from Neutral, signaling improved confidence in the company’s outlook. BTIG upgrades NeoGenomics to Buy
  • Needham raised its price target to $22 from $19 and maintained a Buy rating, implying substantial upside from the referenced share price. Needham raises NeoGenomics price target
  • NeoGenomics issued third-quarter 2026 revenue guidance of $209 million, above the $205.8 million consensus estimate. Full-year revenue guidance of $802 million to $806 million was broadly in line with the $803.8 million consensus. The company’s latest reported quarter also exceeded revenue and EPS expectations, with revenue up 11.2% year over year.
  • Warren Stone was selected as the next CEO, providing a named successor and potentially reducing some uncertainty around the transition. Warren Stone named next NeoGenomics CEO
  • Board changes are scheduled to take effect January 4, 2027, adding another governance transition for investors to monitor. NeoGenomics board changes
  • The stock fell sharply after the CEO succession announcement, despite the revenue beat and solid outlook. Investors appear concerned about execution risk, strategic continuity, and whether the leadership change could disrupt NeoGenomics’ growth trajectory. NeoGenomics falls on CEO succession plan
← Previous Stock of the DayNext Stock of the Day →

Recent News